• education
Search

Sirdalud

Sirdalud

tizanidine

Manufacturer:

Sandoz

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Tizanidine HCl
Indications/Uses
Tab: Painful muscle spasm associated w/ static & functional disorders of spine (cervical & lumbar syndromes) & following surgery eg, herniated intervertebral disc or OA of hip. Tab & MR cap: Spasticity due to neurological disorders eg, multiple sclerosis, chronic myelopathy, degenerative spinal cord diseases, CVA, cerebral palsy.
Click to view Sirdalud detailed prescribing information
Dosage/Direction for Use
Relief of painful muscle spasms 2-4 mg tid. Severe cases May take extra dose of 2 mg or 4 mg preferably at night. Spasticity due to neurological disorders Initial dose: Not to exceed 6 mg daily in 3 divided doses. May be increased stepwise ½ wkly- or wkly-interval by 2-4 mg. Optimum therapeutic response: 12-24 mg in 3 or 4 equally spaced doses. Max daily dose: Not to exceed 36 mg. Elderly Start treatment at lowest dose, & may increase dose according to tolerability & efficacy. Renal impairment (CrCl <25 mL/min) Start treatment at 2 mg once daily, & may increase dose according to tolerability & efficacy.
Click to view Sirdalud detailed prescribing information
Overdosage
View Sirdalud overdosage for action to be taken in the event of an overdose.
Administration
Should be taken on an empty stomach.
Contraindications
Hypersensitivity. Concomitant use w/ strong CYP1A2 inhibitors eg, fluvoxamine or ciprofloxacin. Severely impaired hepatic function.
Click to view Sirdalud detailed prescribing information
Special Precautions
Discontinue use if anaphylaxis or angioedema w/ anaphylactic shock or difficulty of breathing is observed; serum levels of SGPT or SGOT are persistently >3x ULN range. Gradually down titrated & not to be stopped abruptly. Hypotension; rebound HTN & tachycardia. Monitor LFTs mthly for 1st 4 mth in patients receiving doses of ≥12 mg & who develop unexplained nausea, anorexia, or tiredness. Not recommended in concomitant use w/ moderate CYP1A2 inhibitors. Drugs known to increase QT interval. May affect ability to drive & use machines. Consider pregnancy testing prior to starting treatment; use of effective contraception during treatment & for 1 day after discontinuation of treatment in sexually active females of reproductive potential. Not to be used during pregnancy. Not to be given in lactating women. Not recommended in childn <18 yr.
Click to view Sirdalud detailed prescribing information
Adverse Reactions
Somnolence, dizziness; GI disorder, dry mouth; muscular weakness; fatigue. Insomnia, sleep disorder; hypotension; nausea; decreased BP, increased transaminases.
Click to view Sirdalud detailed prescribing information
Drug Interactions
Increased plasma levels w/ drugs known to inhibit CYP1A2 activity. Decreased plasma levels w/ drugs known to induce CYP1A2 activity. Increased AUC w/ fluvoxamine or ciprofloxacin. Co-administration w/ other CYP1A2 inhibitors eg, antiarrhythmics (amiodarone, mexiletine, propafenone), cimetidine, fluoroquinolones (enoxacin, pefloxacin, norfloxacin), rofecoxib, OCs, & ticlopidine. Drugs known to prolong QT interval (including but not limited to cisapride, amitriptyline & azithromycin). Concomitant use w/ antihypertensives, including diuretics. Decreased conc w/ rifampicin. Decreased systemic exposure w/ cigarettes. Enhanced CNS depressant effects of alcohol. Enhanced sedative action w/ sedatives, hypnotics (eg, benzodiazepine or baclofen), & other drug eg, antihistamines. Potential additive hypotensive effect w/ other α-2 adrenergic agonists (eg, clonidine).
Click to view Sirdalud detailed prescribing information
Caution For Usage
For caution against possible variation of physical aspect of medicine... Click to view Sirdalud detailed prescribing information
Storage
View Sirdalud storage conditions for details to ensure optimal shelf-life.
Description
View Sirdalud description for details of the chemical structure and excipients (inactive components).
Action
View Sirdalud mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Muscle Relaxants
ATC Classification
M03BX02 - tizanidine ; Belongs to the class of other centrally-acting muscle relaxants.
Presentation/Packing
Form
Sirdalud tab 2 mg
Packing/Price
10 × 10's
Form
Sirdalud tab 4 mg
Packing/Price
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in